CLINICAL HANDBOOK OF SCHIZOPHRENIA

17. Side Effects of Antipsychotics 177Bai, Y. M., Yu, S. C., Chen, J. Y., Lin, C. Y., Chou, P., & Lin, C. C. (2005). Risperidone for pre-existingsevere tardive dyskinesia: A 48-week prospective follow-up study. International Clinical Psychopharmacology,20, 79–85.Bergman, R. N., & Ader, M. (2005). Atypical antipsychotics and glucose homeostasis. Journal ofClinical Psychiatry, 66, 504–514.Correll, C. U., Leucht, S., & Kane, J. M. (2004). Lower risk for tardive dyskinesia associated with second-generationantipsychotics: A systematic review of 1-year studies. American Journal of Psychiatry,161,414–425.Leslie, D. L., & Rosenheck, R. A. (2004). Incidence of newly diagnosed diabetes attributable to atypicalantipsychotic medications. American Journal of Psychiatry,161, 1709–1711.Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., et al.(2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New EnglandJournal of Medicine, 353, 1209–1223.Lindenmayer, J. P., Czobor, P., Volavka, J., Citrome, L., Sheitman, B., McEvoy, J. P., et al. (2003).Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical oratypical antipsychotics. American Journal of Psychiatry, 160, 290–296.Miller, D. D., McEvoy, J. P., Davis, S. P., Caroff, N., Saltz, B. L., Chakos, M. H., et al. (2005). Clinicalcorrelates of tardive dyskinesia in schizophrenia: Baseline data from the CATIE schizophreniatrial. Schizophrenia Research, 80, 33–43.Rosenbaum, J. F., Arana, G. W., Hyman, S. E., Labbate, L. A., & Fava, M. (Eds.) (2005). Handbook ofpsychiatric drug therapy (5th ed.). Philadelphia: Lippincott Williams & Wilkins.Simpson, G. M., Lee, J. H., Zoubok, B., & Gardos, G. (1979). A rating scale for tardive dyskinesia.Psychopharmacology, 64, 171–179.Wirshing, D.A. (2004). Schizophrenia and obesity: Impact of antipsychotic medications. Journal ofClinical Psychiatry, 65(Suppl. 18), 13–26.